3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
76
Phase NA
34
Phase 1/2
6
Phase 2
5
Phase 4
2
Phase 3
2
Phase 2/3
1
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
592
Neoplasms
296
Carcinoma, Non-Small-Cell Lung
284
Prostatic Neoplasms
266
Colorectal Neoplasms
213
Multiple Myeloma
181
Lung Neoplasms
149
Neoplasm Metastasis
139
Leukemia, Myeloid, Acute
125
Leukemia
120
Lymphoma
114
Lymphoma, Follicular
113
Stomach Neoplasms
105
Lymphoma, Non-Hodgkin
102
Colonic Neoplasms
98
Ovarian Neoplasms
96
Rectal Neoplasms
95
Precursor Cell Lymphoblastic Leukemia-Lymphoma
94
Uterine Cervical Neoplasms
93
Head and Neck Neoplasms
92
Leukemia, Lymphocytic, Chronic, B-Cell
91
Pain
90
Carcinoma, Hepatocellular
86
Pancreatic Neoplasms
81
Melanoma
78
Lymphoma, Large B-Cell, Diffuse
77
Papillomavirus Infections
68
Recurrence
66
Squamous Cell Carcinoma of Head and Neck
64
Parkinson Disease 4, Autosomal Dominant Lewy Body
62
Interventions
Quality of Life
1
Patient Readmission
1
Palliative Care
1
Nivolumab
1
Needs Assessment
1
Coping Skills
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
Advanced Cancer
×
Clear all
NCT02743494
2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3
Completed
794 enrolled
13 charts
1 FDA
NCT01444157
2014-07-18
FamCope
Bispebjerg Hospital
Phase 3
Completed
700 enrolled